Steve Devine

3.1k total citations · 1 hit paper
22 papers, 2.3k citations indexed

About

Steve Devine is a scholar working on Hematology, Oncology and Genetics. According to data from OpenAlex, Steve Devine has authored 22 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Hematology, 9 papers in Oncology and 5 papers in Genetics. Recurrent topics in Steve Devine's work include Hematopoietic Stem Cell Transplantation (9 papers), Acute Myeloid Leukemia Research (4 papers) and Chronic Myeloid Leukemia Treatments (3 papers). Steve Devine is often cited by papers focused on Hematopoietic Stem Cell Transplantation (9 papers), Acute Myeloid Leukemia Research (4 papers) and Chronic Myeloid Leukemia Treatments (3 papers). Steve Devine collaborates with scholars based in United States and Israel. Steve Devine's co-authors include Amelia Bartholomew, Sheila Patil, Annemarie Moseley, Cord Sturgeon, David S. Ucker, Robert Deans, Kevin R. McIntosh, Ronald Hoffman, Karen Ferrer and Koen van Besien and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Antimicrobial Agents and Chemotherapy.

In The Last Decade

Steve Devine

22 papers receiving 2.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo

2002 1.8k citations Amelia Bartholomew, Cord Sturgeon et al. Experimental Hematology profile →

Peers

Countries citing papers authored by Steve Devine

Since Specialization

Citations

This map shows the geographic impact of Steve Devine's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Steve Devine with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Steve Devine more than expected).

Fields of papers citing papers by Steve Devine

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Steve Devine. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Steve Devine. The network helps show where Steve Devine may publish in the future.

Co-authorship network of co-authors of Steve Devine

This figure shows the co-authorship network connecting the top 25 collaborators of Steve Devine. A scholar is included among the top collaborators of Steve Devine based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Steve Devine. Steve Devine is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Results of a Phase III Randomized, Multi-Center Study of Allogeneic Stem Cell Transplantation after High Versus Reduced Intensity Conditioning in Patients with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML): Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0901 2015 ·Blood ·Bart L. Scott, Marcelo C. Pasquini, Brent R. Logan, Juan Wu, Steve Devine, David Porter, Richard T. Maziarz, Erica D. Warlick, Hugo F. Fernández, Edwin P. Alyea, Mehdi Hamadani, Asad Bashey, Sergio Giralt, Eric Leifer, Nancy L. Geller, Jennifer Le‐Rademacher, Adam Mendizabal, Mary M. Horowitz, H. Joachim Deeg, Mitchell E. Horwitz	55
2	The hematopoietic stem cell transplant comorbidity index can predict for 30-day readmission following autologous stem cell transplant for lymphoma and multiple myeloma 2014 ·Bone Marrow Transplantation ·Samantha Jaglowski, (unknown), Craig C. Hofmeister, (unknown), William Blum, Rebecca B. Klisovic, Sumithra Vasu, (unknown), Yvonne A. Efebera, D.M. Benson, Steve Devine, Leslie A. Andritsos	16
3	Minimal Residual Disease (MRD) Status Following Induction Chemo-Immunotherapy Predicts Progression-Free Survival In Mantle Cell Lymphoma (MCL): CALGB 50403 (Alliance) 2013 ·Blood ·Noreen Fulton, Jeffrey Johnson, Lawrence D. Kaplan, (unknown), Greg Malnassy, Sin‐Ho Jung, Steve Devine, Thomas C. Shea, John P. Leonard, Bruce D. Cheson, Wendy Stock	2
4	Higher Busulfan Dose Intensity Does Not Improve Outcomes of Patients Undergoing Allogeneic Hematopoietic Cell Transplantation (AHCT) Following Fludarabine/Busulfan/Atg (FBA)-Based Reduced Toxicity Conditioning (RTC) 2011 ·Biology of Blood and Marrow Transplantation ·Mehdi Hamadani, Michael Craig, Jame Abraham, William Tse, Aaron Cumpston, Laura F. Gibson, Scot C. Remick, (unknown), (unknown), Craig C. Hofmeister, Sam Penza, Leslie A. Andritsos, William Blum, D.M. Benson, Steve Devine	2
5	The Humanized Anti PD-1 Antibody, CT-011, Increases Specific CD4+ Effector/Memory and Memory T Lymphocytes in Patients with Diffuse Large B Cell Lymphoma (DLBCL) Following Autologous Stem Cell Transplantation (AuSCT). 2009 ·Blood ·Rinat Rotem‐Yehudar, Philippe Armand, Steve Devine, Joseph W. Fay, Chitra Hosing, Markus Y. Mapara, (unknown), Joseph P. Uberti, David Avigan, Karen K. Ballen, Jane N. Winter, Arnon Nagler, Leo I. Gordon	2
6	Preliminary results of a phase I trial with dose escalated lenalidomide (L) in separate cohorts of relapsed acute leukemia (AL) or chronic lymphocytic leukemia (CLL): evidence of activity in acute myeloid leukemia (AML) and toxicity in CLL at starting dose 2008 ·Journal of Clinical Oncology ·William Blum, Leslie A. Andritsos, (unknown), Rebecca B. Klisovic, Cheryl Kefauver, Steve Devine, Guido Marcucci, John C. Byrd	1
7	Preliminary Results of a Phase II Study of Low Dose Decitabine as a Single Agent in Older Patients (age≥60) with Previously Untreated Acute Myeloid Leukemia (AML) 2008 ·Blood ·William Blum, Rebecca B. Klisovic, Shujun Liu, Ramiro Garzon, Cheryl Kefauver, Zhongfa Liu, (unknown), Hollie Devine, Steve Devine, Michael R. Grever, Kenneth K. Chan, Miguel A. Villalona‐Calero, John C. Byrd, Guido Marcucci	7
8	Once daily ganciclovir as initial pre-emptive therapy delayed until threshold CMV load ⩾10000 copies/ml: a safe and effective strategy for allogeneic stem cell transplant patients 2005 ·Bone Marrow Transplantation ·(unknown), Gregory A. Storch, Steve Devine, John F. DiPersio, Ravi Vij	30
9	Pharmacokinetic and Maximum Tolerated Dose Study of Micafungin in Combination with Fluconazole versus Fluconazole Alone for Prophylaxis of Fungal Infections in Adult Patients Undergoing a Bone Marrow or Peripheral Stem Cell Transplant 2005 ·Antimicrobial Agents and Chemotherapy ·J. Hiemenz, Pablo J. Cagnoni, David Simpson, Steve Devine, Nelson J. Chao, James J. Keirns, W. Lau, D. Facklam, Donald N. Buell	122
10	Phase II study of autologous transplantation with interleukin-2-incubated peripheral blood stem cells and posttransplantation interleukin-2 in relapsed or refractory non-Hodgkin lymphoma 2004 ·Biology of Blood and Marrow Transplantation ·Koen van Besien, Rakesh Mehra, (unknown), Wendy Stock, Issa F. Khouri, Sergio Giralt, Steve Devine, Amittha Wickrema, David Peace, Jeff Sosman, (unknown), Richard E. Champlin	6
11	Chimerism and clinical outcomes of 110 recipients of unrelated donor bone marrow transplants who underwent conditioning with low-dose, single-exposure total body irradiation and cyclophosphamide 2004 ·Blood ·Mark D. Girgis, (unknown), William Blum, Randy A. Brown, Hsiu-san Lin, H. Jean Khoury, Lawrence T. Goodnough, Ravi Vij, Steve Devine, (unknown), (unknown), (unknown), John F. DiPersio, Douglas Adkins	28
12	Primary amyloidosis patients with significant organ dysfunction tolerate autologous transplantation after conditioning with single-dose total body irradiation alone: a feasibility study 2003 ·Biology of Blood and Marrow Transplantation ·William Blum, H. Jean Khoury, (unknown), Ravi Vij, Lawrence T. Goodnough, Steve Devine, John F. DiPersio, Douglas Adkins	16
13	Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo breakdown → 2002 ·Experimental Hematology ·Amelia Bartholomew, Cord Sturgeon, (unknown), Karen Ferrer, Kevin R. McIntosh, Sheila Patil, (unknown), Steve Devine, David S. Ucker, Robert Deans, Annemarie Moseley, Ronald Hoffman	1788
14	Allogeneic stem cell transplantation for sickle cell disease. A study of patients' decisions 2001 ·Bone Marrow Transplantation ·Koen van Besien, M Koshy, Lisa Anderson-Shaw, (unknown), Louise Dorn, Steve Devine, Mohamed Yassine, Eric Kodish	56
15	Allogeneic and autologous transplantation for chronic lymphocytic leukemia 2001 ·Leukemia ·Koen van Besien, (unknown), Steve Devine, Wendy Stock	26
16	Fludarabine-based conditioning for allogeneic transplantation in adults with sickle cell disease 2000 ·Bone Marrow Transplantation ·Koen van Besien, Amelia Bartholomew, Wendy Stock, David Peace, Steve Devine, Dorie Sher, Jeff Sosman, (unknown), Matthew Koshy, Robert S. Hoffman	77
17	Impact of donor lymphocyte infusion for hematological malignancy relapsed after allogeneic bone marrow transplantation 1998 ·(unknown), Edmund K. Waller, Istvan Redei, (unknown), William H. Fleming, Robert B. Geller, Leonard T. Heffner, Christopher D. Hillyer, Jeannine T. Holden, Kent Holland, (unknown), (unknown), (unknown), (unknown), Glenn E. Rodey, John R. Wingard, Elliott F. Winton, Andrew M. Yeager, Steve Devine	4
18	The outcome of unrelated donor bone marrow transplantation in patients with hematologic malignancies using tacrolimus (FK506) and low dose methotrexate for graft-versus-host disease prophylaxis. 1997 ·PubMed ·Steve Devine, RB Geller, Liming Lin, S P Dix, H. Kent Holland, David Maurer, Kate K. O’Toole, Jesse Keller, (unknown), Leonard T. Heffner, C D Hillyer, Glenn E. Rodey, E. Winton, Rochelle Maher, William E. Fitzsimmons, John R. Wingard	31
19	Tacrolimus (FK506)-induced cerebral blindness following bone marrow transplantation. 1996 ·PubMed ·Steve Devine, Nancy J. Newman, (unknown), Gregory J. Joseph, Tobias Geis, Jerry A. Schneider, RB Geller, John R. Wingard	17
20	Thrombotic thrombocytopenic purpura associated with FK506 following bone marrow transplantation. 1995 ·PubMed ·(unknown), Steve Devine, H. Kent Holland, Robert B. Geller, Kate K. O’Toole, John R. Wingard	30

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact